Tough medicine
26 January 2010
Joe Jimenez has a big todo list at the Swiss drugs group. Shortterm, he must resolve the impasse with minorities at Alcon and raise $16 bln to pay for Nestle’s stake in the eye care firm. The strategic challenge is even greater: maintaining growth as blockbuster patents expire.